Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Anti-ovarian cancer medicinal composition with synergistic effect and application thereof

A technology of synergy and composition, applied in the field of medical scientific research, to achieve the effect of good curative effect, good application prospect, and strong clinical application value

Inactive Publication Date: 2020-07-03
JINSHAN HOSPITAL FUDAN UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, there is no report about a kind of synergistic anti-ovarian cancer pharmaceutical composition and its application of the present invention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-ovarian cancer medicinal composition with synergistic effect and application thereof
  • Anti-ovarian cancer medicinal composition with synergistic effect and application thereof
  • Anti-ovarian cancer medicinal composition with synergistic effect and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1 Cell Viability Determination

[0043] 1 Experimental method

[0044] Cell viability was determined using CCK-8 kit (Dojindo, Japan). Ovarian cancer OVCAR-3 cells were seeded into 96-well plates at a density of 6×10 per well 3cells. In time- and dose-dependent experiments, different concentrations of mangosteen (0, 5, 10, 20, 25, 30 and 50 μM) were added to equal individual wells. Empty (blank, no cells) and cells without drug treatment served as controls. Five wells were replicated for each concentration. After incubation for 24, 48 and 72 h, 10 μl of CCK-8 reagent was added to each well, and then the absorbance of optical density (OD) was read at 490 nm with a microplate reader (BioRad, Hercules, CA, USA) to evaluate the cells vitality.

[0045] For the combined drug experiment of mangosteen and cisplatin, we divided the cells into 3 groups: different doses (0, 5, 10, 20, 25 and 30 μM) of mangosteen were used alone, and different doses (0, 0.5, 1, 2, 4...

Embodiment 2

[0048] Example 2 Cell cycle analysis

[0049] 1 Experimental method

[0050] OVCAR-3 cells (concentration at 1×10 6 / well) were inoculated into 6-well plates and incubated with different concentrations of mangosteen (0, 10, 20 and 25 μM). After 48 hours of culture, the cells were collected by centrifugation, washed with cold phosphate-buffered saline (PBS), and then fixed with 70% cold ethanol overnight at 4°C. Subsequently, cells were incubated with 500 μl PBS containing 50 μg / ml propidium iodide (PI) and 0.1 mg / ml RNaseA (Sigma-Aldrich, USA) for 30 minutes at room temperature. Cellular distribution of the cell cycle was detected by FACSCalibur flow cytometry (BD Biosciences). Experiments were repeated at least three times.

[0051] 2 Experimental results

[0052] Mangosteen induces cycle arrest in ovarian cancer OVCAR-3 cells. OVCAR-3 cells were treated with different concentrations of mangosteen for 48 hours, and then cell cycle analysis was performed by flow cytometr...

Embodiment 3

[0056] Example 3 Detection of apoptotic cells by flow cytometry

[0057] 1 Experimental method

[0058] We used AnnexinV-FITC Apoptosis Detection Kit (BD Biosciences, USA) to detect apoptotic cells. Ovarian cancer OVCAR-3 cells in 2×10 6 Inoculated into a 6-well plate at a density of 1 / well, and after incubation for 24 hours, mangosteen and cisplatin were added to each well. The experiment was divided into three groups: mangostin alone group (20 or 25 μM), cisplatin alone group (2 or 4 μM) and combination group (20 μM mangostin plus 2 μM cisplatin). 3 wells were replicated at each concentration. After 48 hours of incubation with the drug, the cells were collected and washed once with PBS, and then 200 μl of binding buffer containing 5 μl of AnnexinV-FITC (fluorescein isothiocyanate) and 10 μl of PI (propidium iodide) staining solution was added . After incubation at room temperature for 15 minutes, apoptotic cells were detected by flow cytometry analysis. Experiments wer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medical scientific researches and particularly relates to an anti-ovarian cancer medicinal composition and application thereof. The medicinal composition consists of garcinol and cis-platinum, wherein the garcinol and cis-platinum have optimized molar concentrations being 20[mu]M and 2[mu]M respectively. Experimental results indicate that the garcinol and cis-platinum are combined to remarkably inhibit the activity of ovarian cancer cells, remarkably induce cycle arrest of ovarian cancer cells and remarkably induce apoptosis of the ovarian cancercells. The anti-ovarian cancer medicinal composition can overcome defects of large dosage, high toxic and side effect, high relapse rate and the like in medicines for treating ovarian cancer in the prior art, is synergized to induce apoptosis of ovarian cancer cells, reduce medicine dosage, increase cancer cell inhibition rate and reduce toxic and side effects, has an excellent curative effect and has a strong clinical application value.

Description

technical field [0001] The invention relates to the technical field of medical scientific research, in particular to an anti-ovarian cancer pharmaceutical composition with synergistic effect and application thereof. Background technique [0002] As a platinum-based cytotoxic drug, cisplatin (DDP) can cross-link DNA, inhibit DNA replication, and cause protein synthesis to be blocked. Cisplatin is the first-line chemotherapeutic drug for the treatment of ovarian cancer. Although cisplatin is effective for most first-time patients, its clinical application is limited due to its side effects and drug resistance. Therefore, it is necessary to find a suitable synergist or sensitizer combination therapy to reduce the dosage of cisplatin and the side effects of ovarian cancer patients. So far, several plant-derived small-molecule compounds have been reported as potentially effective anticancer drugs, including mangosteen, a polyisopropylated benzophenone derivative extracted from t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/243A61P35/00A61K31/122
CPCA61K33/243A61K31/122A61P35/00A61K2300/00
Inventor 许国雄张洁
Owner JINSHAN HOSPITAL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com